Furthermore, the expression levels of ICGs and exhaustion markers, such as PD‐1 and TIGIT, are at comparable levels between the two tumour types, suggesting that existing immunotherapy targeting PD‐1/PD‐L1 may yield equivalent efficacy for both tumour types. Here, PDCD1 is linked to neoplasm.